Get the Stockscreener App
8.49
8.81%
-0.82
Korro Bio Inc stock is traded at $8.49, with a volume of 129.23K.
It is down -8.81% in the last 24 hours and down -38.61% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.
See More
Previous Close:
$9.31
Open:
$9.32
24h Volume:
129.23K
Relative Volume:
0.68
Market Cap:
$125.02M
Revenue:
$6.39M
Net Income/Loss:
$-117.26M
P/E Ratio:
-0.6803
EPS:
-12.4807
Net Cash Flow:
$-79.08M
1W Performance:
-16.44%
1M Performance:
-38.61%
6M Performance:
-36.97%
1Y Performance:
-82.53%
1-Day Range:
$8.45
$9.38
1-Week Range:
$8.34
$10.26
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
8.49 | 125.02M | 6.39M | -117.26M | -79.08M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-26 | Initiated | Citigroup | Buy |
| Mar-13-26 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Feb-17-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Nearly 49,000 Korro Bio (KRRO) shares sold by director-linked funds - Stock Titan
Korro Bio (KRRO) finance SVP’s 5-share sale comes under a preset trading plan - Stock Titan
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Three new hires get options to buy 5,000 Korro Bio shares - Stock Titan
Senior finance VP at Korro Bio (KRRO) sells 7,353 shares under 10b5-1 trading plan - Stock Titan
Korro Bio unveils OPERA platform to harness natural RNA editing for targeted protein repair - tradersunion.com
Korro Bio (KRRO) director’s 300-share sale via 10b5-1 plan - Stock Titan
Korro to Participate in Upcoming Investor Conferences - The Manila Times
Korro to Participate in Upcoming Investor Conferences - marketscreener.com
Korro to Participate in Upcoming Investor Conferences - Barchart.com
Korro Bio (NASDAQ:KRRO) Director Sells $398,552.00 in Stock - MarketBeat
Korro Bio (KRRO) director-tied funds sell 28K shares on Aug. 19 - Stock Titan
Balyasny Asset Management L.P. Reduces Stake in Korro Bio Inc (K - GuruFocus
Korro Bio Moves KRRO-121 Into First Human Trials, Raising the Stakes in Rare Disease RNA Editing - TipRanks
Korro Bio (NASDAQ:KRRO) Receives "Buy" Rating from HC Wainwright - MarketBeat
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com Nigeria
Korro Bio Advances KRRO-121 Into First Human Trial - TipRanks
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com Canada
Form 8K Korro Bio Inc For: 19 August By Investing.com - Investing.com India
Korro Bio, Inc. Announces Submission To Australian Alfred Health Human Ethics Committee To Initiate First-In-Human Phase 1/2 Clinical Trial For KRRO-121 - marketscreener.com
Korro (KRRO) Quarter in Focus: The Bottom-Line Figure Outpaces Its Comparison in the Latest Reading - vinanet.vn
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
KRRO Q2 2026 Earnings: Wider-Than-Expected Loss Avoided as Cost Discipline Drives 27.65% EPS BeatEarnings Yield Analysis - vinanet.vn
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Barchart.com
Insider Selling: Korro Bio (NASDAQ:KRRO) Director Sells $29,916.28 in Stock - MarketBeat
Korro Bio director Jean Francois Formela sells $29,916 in shares By Investing.com - Investing.com Australia
Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com
Korro Bio director Jean Francois Formela sells $29,916 in shares - Investing.com
Korro Bio (KRRO) director-affiliated funds sell 2,143 shares under 10b5-1 plan - Stock Titan
Korro Bio (NASDAQ:KRRO) Major Shareholder Acquires $19,283.78 in Stock - MarketBeat
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock By Investing.com - Investing.com Canada
Lynx1 Capital, Korro Bio 10% owner, buys $78,809 in stock - Investing.com
Korro Bio (KRRO) holder Lynx1 Capital reports 6,684-share indirect stock purchase - Stock Titan
HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings - marketbeat.com
All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy - Yahoo Finance
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders - webull.com
Analysts Offer Insights on Healthcare Companies: Corbus Pharmaceuticals (CRBP) and Korro Bio (KRRO) - theglobeandmail.com
Korro Bio (NASDAQ:KRRO) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS - marketbeat.com
A US$42m Market Cap Boost Pleasing ToKorro Bio Insiders - simplywall.st
Korro Bio (NASDAQ:KRRO) Upgraded at Wall Street Zen - MarketBeat
H.C. Wainwright Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Korro Bio, Inc. expected to post a loss of $1.43 a shareEarnings Preview - TradingView
Cantor Fitzgerald Maintains Korro Bio(KRRO.US) With Buy Rating, Maintains Target Price $22 - Moomoo
William Blair Maintains Korro Bio(KRRO.US) With Buy Rating - Moomoo
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook - Investing.com UK
Korro Bio Refines Capital Structure with Exchange Agreement - The Globe and Mail
Raymond James reiterates Korro Bio stock rating on hyperammonemia outlook - Investing.com South Africa
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Korro Bio Inc Stock (KRRO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Atlas Venture Opportunity Fund | Shareholder |
Sep 14 '26 |
Proposed Sale |
13.81 |
6,602 |
91,174 |
0 |
| Atlas Venture Fund XI, L.P. | Shareholder |
Sep 14 '26 |
Proposed Sale |
13.81 |
31,888 |
440,373 |
0 |
| Atlas Venture Fund XI, L.P. | Shareholder |
Sep 11 '26 |
Proposed Sale |
13.06 |
8,450 |
110,357 |
0 |
| Atlas Venture Opportunity Fund | Shareholder |
Sep 11 '26 |
Proposed Sale |
13.06 |
1,750 |
22,855 |
0 |
| Dolan Oliver | Officer |
Sep 11 '26 |
Proposed Sale |
13.72 |
5 |
69 |
0 |
| FORMELA JEAN FRANCOIS | Director |
Sep 11 '26 |
Sale |
13.99 |
10,200 |
142,698 |
139,252 |
| Dolan Oliver | Senior Vice President, Finance |
Sep 11 '26 |
Sale |
13.72 |
5 |
69 |
16,241 |
| Dolan Oliver | Officer |
Sep 09 '26 |
Proposed Sale |
13.60 |
6 |
82 |
0 |
| Dolan Oliver | Senior Vice President, Finance |
Sep 09 '26 |
Sale |
13.60 |
6 |
82 |
16,246 |
| Dolan Oliver | Senior Vice President, Finance |
Sep 08 '26 |
Sale |
13.51 |
7,347 |
99,286 |
16,252 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):